ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
ANAB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ANAB has a great financial health rating, but its profitability evaluates not so good. ANAB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ANAB has reported negative net income.
In the past year ANAB has reported a negative cash flow from operations.
In the past 5 years ANAB always reported negative net income.
ANAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ANAB has a better Return On Assets (-36.17%) than 64.51% of its industry peers.
With a Return On Equity value of -185.73%, ANAB is not doing good in the industry: 70.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.17% | ||
| ROE | -185.73% | ||
| ROIC | N/A |
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ANAB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANAB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANAB has less shares outstanding
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.89, we must say that ANAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ANAB (-0.89) is comparable to the rest of the industry.
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.89 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
ANAB has a Current Ratio of 10.87. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ANAB (10.87) is better than 82.25% of its industry peers.
ANAB has a Quick Ratio of 10.87. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
ANAB has a better Quick ratio (10.87) than 82.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.87 | ||
| Quick Ratio | 10.87 |
3. Growth
3.1 Past
The earnings per share for ANAB have decreased strongly by -33.04% in the last year.
ANAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.72%.
ANAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.97% yearly.
EPS 1Y (TTM)-33.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-70.97%
Revenue 1Y (TTM)66.72%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Revenue growth Q2Q32.23%
3.2 Future
The Earnings Per Share is expected to decrease by -1.29% on average over the next years.
Based on estimates for the next years, ANAB will show a very strong growth in Revenue. The Revenue will grow by 55.65% on average per year.
EPS Next Y-5.98%
EPS Next 2Y-0.23%
EPS Next 3Y-5.05%
EPS Next 5Y-1.29%
Revenue Next Year50.13%
Revenue Next 2Y38.64%
Revenue Next 3Y6.87%
Revenue Next 5Y55.65%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANAB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ANAB's earnings are expected to decrease with -5.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.23%
EPS Next 3Y-5.05%
5. Dividend
5.1 Amount
No dividends for ANAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANAPTYSBIO INC
NASDAQ:ANAB (5/3/2024, 7:00:00 PM)
After market: 26.345 -0.23 (-0.88%)26.58
+0.24 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap726.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.17% | ||
| ROE | -185.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.87 | ||
| Quick Ratio | 10.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)66.72%
Revenue growth 3Y-38.84%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y